The spinout of Yamaguchi University and National Cancer Centre Japan has raised the cash from investors including Dai-ichi Life and Binex.
Noile-Immune Biotech, a Japan-based developer of chimeric antigen receptor T-cell therapy for solid tumours spun out of Yamaguchi University and National Cancer Centre Japan, has raised ¥2.38bn ($21.9m) in series C funding.
The round was backed by insurer Dai-ichi Life, pharmaceutical firm Binex, biotech firm Bigen and packaging plant operator Shibuya Kogyo, as well as Binex Holdings, Healthcare Innovation Investment and KD Bio Investment Fund.
Founded in 2015, Noile-Immune is working on cancer immunotherapies. Its lead programme, NIB-101,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
